Indeed, in a recent UK survey, almost 75% of rheumatologists said that they would start treatment with a disease modifying anti-rheumatic drug (DMARD) in patients with positive ACPA, MSK symptoms and US-detected PD signal, in the absence of any clinical synovitis [34]. The gene discussed is PRTN3; the disease is synovitis.